Join Mark Duncan, MD and Caleb Banta-Green, PhD, MPH, MSW in describing the characteristics of extended release naltrexone (Vivitrol), the evidence base for its effectiveness, and the complexities around starting patients on this opioid-blocking medication. They will also address its particular usefulness in certain treatment settings, the challenges to long-term adherence, and contrast its mechanism to the other principal opioid treatment medications.
This presentation is brought to you by:
- University of Washington AIMS Center
- University of Washington ADAI
- Division of Behavioral Health and Recovery (DBHR)